Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Biomarkers Identified for Type 2 Diabetes

By LabMedica International staff writers
Posted on 24 Oct 2012
Novel biomarkers have been identified for type 2 diabetes that can serve as basis for developing new methods of treatment and prevention of this metabolic disease.

Metabolites in the blood have been characterized that will provide insight into the pathological mechanisms of type 2 diabetes and in addition can be used as biomarkers to determine the disease risk.

A scientific team at the German Institute of Human Nutrition (Potsdam-Rehbruecke, Germany) and the Max Delbrueck Center for Molecular Medicine (Berlin, Germany) studied 4,000 blood samples. At the time the blood sample was taken, none of the study participants suffered from type 2 diabetes. However, during the average follow-up time of seven years, 891 participants were diagnosed with type 2 diabetes. There were 76 participants in the study who were already classified at the beginning of the study as individuals at high risk for type 2 diabetes, but at the time the blood sample was taken, they were still healthy.

Flow injection analysis tandem mass spectrometry was used to quantify 163 metabolites per blood sample, including acylcarnitines, amino acids, hexose, and phospholipids, in baseline serum samples. Serum hexose; phenylalanine; and diacyl-phosphatidylcholines C32:1, C36:1, C38:3, and C40:5 were independently associated with increased risk of type 2 diabetes. Serum glycine; sphingomyelin C16:1; acyl-alkyl-phosphatidylcholines C34:3, C40:6, C42:5, C44:4, and C44:5; and lysophosphatidylcholine C18:2 were associated with decreased risk.

The metabolites significantly improved type 2 diabetes prediction compared with established risk factors. They were further linked to insulin sensitivity and secretion in one study group and were partly replicated in the independent cohort. The data indicate that metabolic alterations, including sugar metabolites, amino acids, and choline-containing phospholipids, are associated early on with a higher risk of type 2 diabetes.

Tobias Pischon, MD MPH, the lead author, said “At the same time the metabolites can also be used as biomarkers to precisely determine the risk of diabetes at a very early stage, since the study is based on prospective data, which is data that were collected before the onset of the disease. The results of the new metabolomic analysis thus provide a good basis for developing new treatment and prevention methods." The study was published on October 4, 2012, in the journal Diabetes.

Related Links:

German Institute of Human Nutrition
Max Delbrueck Center for Molecular Medicine



Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
HPV Molecular Controls
ZeptoMetrix® HPV Type 16, 18, 45 & 68 Molecular Controls
New
Community-Acquired Pneumonia Test
RIDA UNITY CAP Bac
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.